Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 4, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MIRABEGRON IN OLDER ADULT SUBJECTS WITH OVERACTIVE BLADDER (OAB)

Intervention/treatment:
MYRBETRIQ (MIRABEGRON)
Medical condition:
OVERACTIVE BLADDER
Protocol code:
178-MA-1005
Control number:
179787
Status:
Closed
Approved:
December 17, 2014
Date Completed:
Trial phase:
Phase 4
For more information:
ClinicalTrials.gov - NCT02216214
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
65 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Clinical Trial Disclosure
Organization
Astellas Pharma Global Development, Inc.
Phone:
800-888-7704
Sponsor
ASTELLAS PHARMA GLOBAL DEVELOPMENT INC

Locations

Site CA00160
Québec, G1X 0B6

Alberta

Site CA00130
Edmonton, Alberta, T5G 0B7

British Columbia

Site CA00074
Vancouver, British Columbia, V6J1S3

Ontario

Site CA00116
Sarnia, Ontario, N7T4X3
Site CA00118
London, Ontario, N6A 4V2
Site CA00123
Corunna, Ontario, N0N1G0
Site CA00126
Hamilton, Ontario, L8N 4A6
Site CA00129
Québec, Ontario, G1S2L6
Site CA00155
Brampton, Ontario, L6T 4S5
Site CA00168
Toronto, Ontario, M4S 1Y2
Site CA00169
Greater Sudbury, Ontario, P3E 3Z9

Quebec

Site CA00061
Sherbrooke, Quebec, J1H5N2
Site CA00073
Point Claire, Quebec, H9R4S3
Site CA00106
Point Claire, Quebec, H9R4S3
Site CA00156
Sherbrooke, Quebec, J1H 1Z1
Site CA00158
Montreal, Quebec, H2Y 1S1
Site CA00164
Lévis, Quebec, G6W 0M6

Results

See the results from the trial NCT02216214. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?